UY31258A1 - Anticuerpos y fragmentos de anticuerpos ant ephb4 - Google Patents

Anticuerpos y fragmentos de anticuerpos ant ephb4

Info

Publication number
UY31258A1
UY31258A1 UY31258A UY31258A UY31258A1 UY 31258 A1 UY31258 A1 UY 31258A1 UY 31258 A UY31258 A UY 31258A UY 31258 A UY31258 A UY 31258A UY 31258 A1 UY31258 A1 UY 31258A1
Authority
UY
Uruguay
Prior art keywords
antibodies
ephb4
fragments
ant
comprise heavy
Prior art date
Application number
UY31258A
Other languages
English (en)
Inventor
Catrin Pracht
Stefan Steidl
Andreas Popp
Jens Glienke
Heike Petrul
Josef Prassler
Jorg Willuda
Andrea Menrad
Dieter Zopf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of UY31258A1 publication Critical patent/UY31258A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La invencion se relaciona con anticuerpos y fragmentos de anticuerpos que reconocen específicamente el receptor EphB4, los cuales comprenden cadenas pesadas y cadenas livianas, y comprenden CDR pesadas y livianas, y su uso como medicamento para el tratamiento de la angiogénesis patologica, en particular, en la terapia del cáncer.
UY31258A 2007-07-31 2008-07-30 Anticuerpos y fragmentos de anticuerpos ant ephb4 UY31258A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07075657A EP2020419A1 (en) 2007-07-31 2007-07-31 Anti ephB4 antibody fragments
US95377107P 2007-08-03 2007-08-03

Publications (1)

Publication Number Publication Date
UY31258A1 true UY31258A1 (es) 2009-03-02

Family

ID=38739892

Family Applications (1)

Application Number Title Priority Date Filing Date
UY31258A UY31258A1 (es) 2007-07-31 2008-07-30 Anticuerpos y fragmentos de anticuerpos ant ephb4

Country Status (9)

Country Link
US (1) US20090137002A1 (es)
EP (2) EP2020419A1 (es)
AR (1) AR067730A1 (es)
CL (1) CL2008002233A1 (es)
PA (1) PA8791201A1 (es)
PE (1) PE20090906A1 (es)
TW (1) TW200911836A (es)
UY (1) UY31258A1 (es)
WO (1) WO2009015908A2 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012021841A2 (en) * 2010-08-12 2012-02-16 Attogen Inc. Antibody molecules to oncogenic isoforms of fibroblast growth factor receptor-2 and uses thereof
WO2009100105A2 (en) * 2008-02-04 2009-08-13 Attogen Inc. Inhibitors of oncogenic isoforms and uses thereof
US9260525B2 (en) 2008-02-04 2016-02-16 Xiao-Jia Chang Antibody molecules to oncogenic isoforms of fibroblast growth factor receptor-2 and uses thereof
WO2011037791A1 (en) * 2009-09-25 2011-03-31 Merck Sharp & Dohme Corp. Antagonists of pcsk9
JP5774595B2 (ja) 2009-10-28 2015-09-09 ヤンセン バイオテツク，インコーポレーテツド 抗ｇｌｐ−１ｒ抗体及びそれらの使用
CN109069627A (zh) 2016-01-14 2018-12-21 纪念斯隆-凯特琳癌症中心 对foxp3衍生肽特异性的t细胞受体样抗体
CN113398267B (zh) * 2020-03-17 2023-05-05 中国医学科学院药物研究所 EphB4作为靶标在筛选增加胰岛素敏感性药物或模型中的应用
WO2023283211A2 (en) * 2021-07-08 2023-01-12 The Children's Medical Center Corporation Cd21 antibodies and uses thereof
CN114409792B (zh) * 2021-12-01 2022-08-12 中山大学附属第五医院 抗EphB4纳米抗体

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5635177A (en) * 1992-01-22 1997-06-03 Genentech, Inc. Protein tyrosine kinase agonist antibodies
WO2005090406A2 (en) * 2004-03-12 2005-09-29 Vasgene Therapeutics, Inc. Antibodies binding to ephb4 for inhibiting angiogenesis and tumor growth
TWI596111B (zh) * 2006-01-05 2017-08-21 建南德克公司 抗ｅｐｈｂ４抗體及使用該抗體之方法

Also Published As

Publication number Publication date
US20090137002A1 (en) 2009-05-28
PA8791201A1 (es) 2009-05-15
TW200911836A (en) 2009-03-16
EP2020419A1 (en) 2009-02-04
EP2170955A2 (en) 2010-04-07
WO2009015908A3 (en) 2009-03-26
AR067730A1 (es) 2009-10-21
WO2009015908A2 (en) 2009-02-05
PE20090906A1 (es) 2009-08-08
CL2008002233A1 (es) 2009-10-09

Similar Documents

Publication Publication Date Title
UY31258A1 (es) Anticuerpos y fragmentos de anticuerpos ant ephb4
ECSP18073836A (es) Moléculas de unión a bcma y métodos de uso de las mismas
GT201700102A (es) Conjugados de anticuerpo-fármaco
CL2017001916A1 (es) Conjugados anti-dll3 (ligando3 tipo delta) manipulados y métodos de uso (divisional solicitud 468-2016)
CO2018011364A2 (es) Anticuerpos anti-il-33, composiciones, métodos y usos de los mismos
CL2018000458A1 (es) Conjugados anticuerpo anti-dll3-fármaco y métodos de uso
CO2020010277A2 (es) Moléculas de unión a antígeno dirigidas a her2 que comprenden 4-1bbl
CL2013000459A1 (es) Anticuerpo aislado o fragmento que se enlaza a un estado inactivo de un receptor her; composicion farmaceutica que lo comprende; uso del anticuerpo para tratar cancer.
CR20120454A (es) Proteínas terapéuticas de unión a dll4
AR096015A1 (es) Conjugados de fármacos con anticuerpos
CU20150128A7 (es) Conjugados fármaco-anticuerpo
CO6290772A2 (es) Anticuerpos dirigidos a angiopoietina 1 y angiopoietina 2 y usos de los mismos
DOP2012000052A (es) Proteínas terapéuticas de unión a dll4
PH12017500002A1 (en) Anti-cdh6 antibody drug conjugates
CL2018001722A1 (es) Nuevos anticuerpos anti-mfi2 y métodos de uso (divisional solicitud 201700506)
CR20120522A (es) Pirrolobenzodiacepinas y conjugados de las mismas
CL2012001141A1 (es) Anticuerpo aislado o fragmento de este que se une específicamente a interleuquina-17a (il-17a) humana.
CL2012000229A1 (es) Anticuerpo humano aislado o un fragmento del mismo de unión al antígeno, que se une específicamente a la angiopoyetina-2 humana (hang-2) pero que no se une sustancialmente a la hang-1; composición farmacéutica que lo comprende; y su uso para el tratamiento de un tumor, hipertensión, diabetes, edema, enfermedad renal u ocular.
ECSP11011445A (es) Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c3b
UY32061A (es) Anticuerpos humanos para rankl humano
CO6571881A2 (es) Nuevos anticuerpos anti-cxcr4 humanizados para el tratamiento del cáncer
CO2022007924A2 (es) Conjugados de anticuerpo y fármaco de eribulina anti-mesotelina y métodos de uso
CL2018001238A1 (es) Moléculas de unión específicas para asct2 y usos de las mismas

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20171011